These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29118552)

  • 1. Drugs for improving esophageal mucosa defense: where are we now and where are we going?
    Savarino E; Zentilin P; Marabotto E; Pellegatta G; Coppo C; Brunacci M; Dulbecco P; Savarino V
    Ann Gastroenterol; 2017; 30(6):585-591. PubMed ID: 29118552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.
    Yadlapati R; Gyawali CP; Pandolfino JE;
    Clin Gastroenterol Hepatol; 2022 May; 20(5):984-994.e1. PubMed ID: 35123084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.
    Chen JW; Vela MF; Peterson KA; Carlson DA
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1414-1421.e3. PubMed ID: 37061897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: a systematic review and meta-analysis of controlled trials].
    Bordin DS; Andreev DN; Maev IV
    Ter Arkh; 2023 Jan; 94(12):1407-1412. PubMed ID: 37167186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
    Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment of GERD: Where we are now, and where are we going?
    Scarpignato C; Hongo M; Wu JCY; Lottrup C; Lazarescu A; Stein E; Hunt RH
    Ann N Y Acad Sci; 2020 Dec; 1482(1):193-212. PubMed ID: 32935346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].
    Lee KJ
    Korean J Gastroenterol; 2015 Aug; 66(2):70-4. PubMed ID: 26289239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium-competitive acid blockers and gastroesophageal reflux disease.
    Leowattana W; Leowattana T
    World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology.
    Surdea-Blaga T; Băncilă I; Dobru D; Drug V; Frățilă O; Goldiș A; Grad SM; Mureșan C; Nedelcu L; Porr PJ; Sporea I; Dumitrascu DL
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):537-546. PubMed ID: 27981311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Esophageal Mucosal Integrity in Patients with Gastroesophageal Reflux Disease.
    Matsumura T; Arai M; Ishigami H; Fujie M; Ishikawa K; Akizue N; Taida T; Ohta Y; Hamanaka S; Okimoto K; Saito K; Maruoka D; Nakagawa T; Kato N
    Digestion; 2018; 97(1):31-37. PubMed ID: 29393167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient journey in gastroesophageal reflux disease: real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists.
    Pasta A; Pelizzaro F; Marabotto E; Calabrese F; Formisano E; Djahandideh Sheijani S; Brandimarte G; Manes G; Gravina AG; Savarino EV
    Therap Adv Gastroenterol; 2024; 17():17562848241239590. PubMed ID: 38524789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection and regeneration of esophageal, pharyngeal, and laryngeal mucosa as a major element in therapy of patients with esophageal and extraesophageal reflux symptoms.
    Gąsiorowska A
    Otolaryngol Pol; 2020 Aug; 74(4):40-45. PubMed ID: 32909960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
    Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
    Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease.
    Savarino V; Marabotto E; Zentilin P; Furnari M; Bodini G; De Maria C; Tolone S; De Bortoli N; Frazzoni M; Savarino E
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):437-449. PubMed ID: 32253948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art.
    Savarino V; Marabotto E; Zentilin P; Demarzo MG; de Bortoli N; Savarino E
    Drug Des Devel Ther; 2021; 15():1609-1621. PubMed ID: 33907381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.
    Rohof WO; Bennink RJ; de Jonge H; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1647-55. PubMed ID: 24184737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
    Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
    J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.